Current status of nanomedicine for breast cancer treatment

  1. Fraguas-Sanchez, A.I. 1
  2. Martin-Sabroso, C. 1
  3. Fernandez-Carballido, A. 1
  4. Torres-Suarez, A.I. 1
  1. 1 Universidad Complutense de Madrid
    info

    Universidad Complutense de Madrid

    Madrid, España

    ROR 02p0gd045

Libro:
Targeted Nanomedicine for Breast Cancer Therapy
  1. Shivani Paliwal (ed. lit.)
  2. Rishi Paliwal (ed. lit.)

Editorial: Elsevier

ISBN: 9780128244760,  9780323860048

Año de publicación: 2022

Páginas: 65-110

Tipo: Capítulo de Libro

DOI: 10.1016/B978-0-12-824476-0.00014-0 GOOGLE SCHOLAR lock_openAcceso abierto editor

Resumen

Chemotherapy represents a mainstay in breast cancer therapy, especially in advanced or metastatic disease or in certain types of breast cancer such as triple-negative breast tumors. The chemotherapeutic agents available today show, in general, a high toxicity due to their nonspecific distribution. Moreover, some of them show a high lipophilicity and require the use of organic solvents for their administration, which increase the overall toxicity of the formulation. The use of nanocarriers for their administration could resolve these challenges, eliminating the use of organic solvents and resulting in a more selective location of the drug at the tumor mass, which would allow for a decrease in the drug toxicity and an increase its efficacy. Chemo-nanotherapy represents an excellent strategy in the treatment of breast cancer, with 10 nanomedicines marketed and 21 nanoformulations in clinical research. However, despite all their advantages, the final approval of new nanomedicines for breast cancer has some limitations, including the toxicity related to the small size of nanocarriers, the lack of correlation of preclinical/clinical efficacy, the high costs of their industrial production, and the difficulty in obtaining reproducible large batches.

Referencias bibliográficas

  • Patra, (2018), J. Nanobiotechnol., 16, 10.1186/s12951-018-0392-8
  • Fraguas-Sánchez, (2019), Cancer Chemother. Pharmacol., 84, pp. 689, 10.1007/s00280-019-03910-6
  • Golombek, (2018), Adv. Drug. Deliv. Rev., 130, pp. 17, 10.1016/j.addr.2018.07.007
  • Greish, (2010), Methods Mol. Biol., 624, pp. 25, 10.1007/978-1-60761-609-2_3
  • Maeda, (2013), Adv. Drug. Deliv. Rev., 65, pp. 71, 10.1016/j.addr.2012.10.002
  • Bazak, (2015), J. Cancer Res. Clin. Oncol., 141, pp. 769, 10.1007/s00432-014-1767-3
  • Danhier, (2016), J. Control. Release, 244, pp. 108, 10.1016/j.jconrel.2016.11.015
  • Kopeckova, (2019), Biomed. Pap., 163, pp. 122, 10.5507/bp.2019.010
  • Serrano Lopez, (2013), pp. 337
  • Saravanakumar, (2019), Curr. Pharm. Des., 25, pp. 2609, 10.2174/1381612825666190709221141
  • Zhou, (2018), Int. J. Nanomed., 13, pp. 2921, 10.2147/IJN.S158696
  • Waks, (2019), JAMA—J. Am. Med. Assoc., 321, pp. 288, 10.1001/jama.2018.19323
  • Samaan, (2019), Biomolecules
  • Nehate, (2014), Current Drug. Deliv., 11, pp. 666, 10.2174/1567201811666140609154949
  • Desai, (2006), Clin. Cancer Res., 12, pp. 1317, 10.1158/1078-0432.CCR-05-1634
  • Asensio-López, (2017), PLoS ONE, 12, 10.1371/journal.pone.0172803
  • Luu, (2018), JACC: Basic Transl. Sci., 3, pp. 861
  • Akbarzadeh, (2013), Nanoscale Res. Lett., 8, 10.1186/1556-276X-8-102
  • Gabizon, (2016), Drug. Resist. Updat., 29, pp. 90, 10.1016/j.drup.2016.10.003
  • Alavi, (2019), Drug. Metab. Pers. Ther., 34
  • D’souza, (2016), Expert. Opin. Drug. Deliv., 13, pp. 1257, 10.1080/17425247.2016.1182485
  • Tahover, (2015), Anti-Cancer Drugs, 26, pp. 241, 10.1097/CAD.0000000000000182
  • Dong, (2018), OncoTargets Ther., 11, pp. 4247, 10.2147/OTT.S162003
  • Dellapasqua, (2011), Breast, 20, pp. 319, 10.1016/j.breast.2011.02.014
  • Gil-Gil, (2015), Breast Cancer Res. Treat., 151, pp. 597, 10.1007/s10549-015-3415-2
  • Martin-Romano, (2018), Breast J., 24, pp. 473, 10.1111/tbj.12975
  • Rayson, (2012), Ann. Oncol., 23, pp. 1780, 10.1093/annonc/mdr519
  • Rocca, (2017), Cancer Chemother. Pharmacol., 79, pp. 863, 10.1007/s00280-017-3279-8
  • Alibolandi, (2017), J. Control. Release, 264, pp. 228, 10.1016/j.jconrel.2017.08.030
  • Trudeau, (2009), J. Clin. Oncol., 27, pp. 5906, 10.1200/JCO.2009.22.7504
  • Szebeni, (2011), Adv. Drug. Deliv. Rev., 63, pp. 1020, 10.1016/j.addr.2011.06.017
  • Bulbake, (2017), Pharmaceutics, 9
  • Batist, (2001), J. Clin. Oncol., 19, pp. 1444, 10.1200/JCO.2001.19.5.1444
  • Giotta, (2007), Ann. Oncol., 18, pp. vi66, 10.1093/annonc/mdm228
  • Lorusso, (2014), Int. J. Oncol., 45, pp. 2137, 10.3892/ijo.2014.2604
  • Rosati, (2011), Ann. Oncol., 22, pp. 315, 10.1093/annonc/mdq392
  • Curtit, (2011), Eur. J. Cancer, 47, pp. 2396, 10.1016/j.ejca.2011.08.004
  • Venturini, (2010), Breast, 19, pp. 333, 10.1016/j.breast.2010.01.018
  • Amadori, (2011), Eur. J. Cancer, 47, pp. 2091, 10.1016/j.ejca.2011.05.005
  • Bernabeu, (2017), Int. J. Pharm., 526, pp. 474, 10.1016/j.ijpharm.2017.05.016
  • Wang, (2013), Mol. Med. Rep., 7, pp. 947, 10.3892/mmr.2013.1264
  • Straubinger, (1993), J. Natl. Cancer Inst. Monogr., 15, pp. 69
  • Zhang, (2009), Biomed. Pharmacother., 63, pp. 603, 10.1016/j.biopha.2008.10.001
  • Merlot, (2014), Front. Physiol., pp. 5
  • Yardley, (2015), J. Clin. Oncol., 33, pp. 1609, 10.1200/JCO.2014.56.2959
  • Kundranda, (2015), Drug Des. Dev. Ther., 9, pp. 3767, 10.2147/DDDT.S88023
  • Lluch, (2014), Crit. Rev. Oncol./Hemat., 89, pp. 62, 10.1016/j.critrevonc.2013.08.001
  • Feng, (2014), Curr. Pharm. Des., 20, pp. 6182, 10.2174/1381612820666140619123255
  • Ota, (2019), Anticancer. Res., 39, pp. 6903, 10.21873/anticanres.13910
  • Gradishar, (2005), J. Clin. Oncol., 23, pp. 7794, 10.1200/JCO.2005.04.937
  • Untch, (2016), Lancet Oncol., 17, pp. 345, 10.1016/S1470-2045(15)00542-2
  • Untch, (2019), J. Clin. Oncol., 37, pp. 2226, 10.1200/JCO.18.01842
  • Shigematsu, (2015), Clin. Breast Cancer, 15, pp. 110, 10.1016/j.clbc.2014.09.010
  • Wang, (2018), Front. Pharmacol., pp. 9
  • Fan, (2019), Curr. Med. Chem., 26, pp. 2356, 10.2174/0929867324666171121102255
  • Oerlemans, (2010), Pharm. Res., 27, pp. 2569, 10.1007/s11095-010-0233-4
  • Young, (2001), Cancer Res. Treat., pp. 451
  • Lee, (2008), Breast Cancer Res. Treat., 108, pp. 241, 10.1007/s10549-007-9591-y
  • Park, (2017), Cancer Res. Treat., 49, pp. 569, 10.4143/crt.2016.289
  • Lee, (2014), J. Breast Cancer, 17, pp. 344, 10.4048/jbc.2014.17.4.344
  • Chen, (2017), Theranostics, 7, pp. 538, 10.7150/thno.16684
  • Giodini, (2017), Nanomed.: Nanotechnol. Biol. Med., 13, pp. 583, 10.1016/j.nano.2016.07.012
  • Madaan, (2013), Clin. Transl. Oncol., 15, pp. 26, 10.1007/s12094-012-0883-2
  • Brahmachari, (2011), Indian. J. Pharmacol., 43, pp. 126, 10.4103/0253-7613.77341
  • Ranade, (2013), Ann. Oncol., 24, pp. v6, 10.1093/annonc/mdt322
  • Thomas, (2016), Lancet. Oncol., 17, 10.1016/S1470-2045(16)30030-4
  • Birrer, (2019), J. Natl. Cancer Inst., 111, pp. 538, 10.1093/jnci/djz035
  • Kalim, (2017), Drug Des. Dev. Ther., 11, pp. 2265, 10.2147/DDDT.S135571
  • Lambert, (2014), J. Med. Chem., 57, pp. 6949, 10.1021/jm500766w
  • Verma, (2012), N. Engl. J. Med., 367, pp. 1783, 10.1056/NEJMoa1209124
  • Diéras, (2017), Lancet Oncol., 18, pp. 732, 10.1016/S1470-2045(17)30312-1
  • Krop, (2014), Lancet Oncol., 15, pp. 689, 10.1016/S1470-2045(14)70178-0
  • Krop, (2017), Lancet Oncol., 18, pp. 743, 10.1016/S1470-2045(17)30313-3
  • Von Minckwitz, (2019), N. Engl. J. Med., 380, pp. 617, 10.1056/NEJMoa1814017
  • Ogitani, (2016), Clin. Cancer Res., 22, pp. 5097, 10.1158/1078-0432.CCR-15-2822
  • Keam, (2020), Drugs, 80, pp. 501, 10.1007/s40265-020-01281-4
  • Nakada, (2019), Chem. Pharm. Bull., 67, pp. 173, 10.1248/cpb.c18-00744
  • Doi, (2017), Lancet Oncol., 18, pp. 1512, 10.1016/S1470-2045(17)30604-6
  • Shitara, (2019), Lancet Oncol., 20, pp. 827, 10.1016/S1470-2045(19)30088-9
  • Syed, (2020), Drugs, 80, pp. 1019, 10.1007/s40265-020-01337-5
  • Goldenberg, (2018), Oncotarget, 9, pp. 28989, 10.18632/oncotarget.25615
  • Zeybek, (2020), Sci. Rep., 10, 10.1038/s41598-020-58009-3
  • Goldenberg, (2015), Oncotarget, 6, pp. 22496, 10.18632/oncotarget.4318
  • Bardia, (2019), N. Engl. J. Med., 380, pp. 741, 10.1056/NEJMoa1814213
  • Bardia, (2017), J. Clin. Oncol., 35, pp. 2141, 10.1200/JCO.2016.70.8297
  • Rajappa, (2018), Oncol. Lett., 16, pp. 3757
  • Jain, (2016), Breast Cancer Res. Treat., 156, pp. 125, 10.1007/s10549-016-3736-9
  • Swenson, (2015), PLoS One, 10, 10.1371/journal.pone.0139752
  • Bi, (2019), Asian J. Pharm. Sci., 14, pp. 365, 10.1016/j.ajps.2018.07.006
  • Nardecchia, (2019), Nanomaterials, 9, 10.3390/nano9020191
  • Zagar, (2014), Int. J. Hyperth., 30, pp. 285, 10.3109/02656736.2014.936049
  • Reynolds, (2012), Toxicol. Appl. Pharmacol., 262, pp. 1, 10.1016/j.taap.2012.04.008
  • Munster, (2018), Br. J. Cancer, 119, pp. 1086, 10.1038/s41416-018-0235-2
  • Kathy, (2016), BMC Cancer
  • Mamot, (2012), Lancet Oncol., 13, pp. 1234, 10.1016/S1470-2045(12)70476-X
  • Christopeit, (2008), Chemotherapy, 54, pp. 309, 10.1159/000151352
  • Strieth, (2014), Head. Neck, 36, pp. 976, 10.1002/hed.23397
  • Awada, (2014), Ann. Oncol., 25, pp. 824, 10.1093/annonc/mdu025
  • Ignatiadis, (2016), PLoS ONE, 11, 10.1371/journal.pone.0154009
  • Slingerland, (2013), Clin. Therap., 35, pp. 1946, 10.1016/j.clinthera.2013.10.009
  • Fetterly, (2008), Clin. Cancer Res., 14, pp. 5856, 10.1158/1078-0432.CCR-08-1046
  • Zahednezhad, (2020), Expert. Opin. Drug. Deliv., 17, pp. 523, 10.1080/17425247.2020.1737672
  • Pourhassan, (2017), J. Control. Release, 261, pp. 163, 10.1016/j.jconrel.2017.06.024
  • Hugger, (2018), J. Clin. Oncol., pp. e13077
  • Deeken, (2013), Cancer Chemother. Pharmacol., 71, pp. 627, 10.1007/s00280-012-2048-y
  • Pereira, (2016), Int. J. Pharm., 514, pp. 150, 10.1016/j.ijpharm.2016.06.057
  • Mahalingam, (2014), Cancer Chemother. Pharmacol., 74, pp. 1241, 10.1007/s00280-014-2602-x
  • Le Rhun, (2020), Neuro-Oncol., 22, pp. 524, 10.1093/neuonc/noz201
  • Caruso, (2012), Chem. Soc. Rev., 41, pp. 2537, 10.1039/c2cs90005j
  • Hamaguchi, (2007), Br. J. Cancer, 97, pp. 170, 10.1038/sj.bjc.6603855
  • Kato, (2012), Invest. N. Drugs, 30, pp. 1621, 10.1007/s10637-011-9709-2
  • Fujiwara, (2019), Br. J. Cancer, 120, pp. 475, 10.1038/s41416-019-0391-z
  • Mukai, (2016), Invest. N. Drugs, 34, pp. 750, 10.1007/s10637-016-0381-4
  • Fujita, (2015), World J. Gastroenterol., 21, pp. 12234, 10.3748/wjg.v21.i43.12234
  • Hamaguchi, (2010), Clin. Cancer Res., 16, pp. 5058, 10.1158/1078-0432.CCR-10-0387
  • Burris, (2016), Cancer Chemother. Pharmacol., 77, pp. 1079, 10.1007/s00280-016-2986-x
  • Dokter, (2014), Mol. Cancer Therap., 13, pp. 2618, 10.1158/1535-7163.MCT-14-0040-T
  • Elgersma, (2015), Mol. Pharm., 12, pp. 1813, 10.1021/mp500781a
  • Rinnerthaler, (2019), Int. J. Mol. Sci., 20, 10.3390/ijms20051115
  • Aftimos, (2017), Cancer Res., 77, pp. P6
  • Cristina, (2018), J. Clin. Oncol., pp. 1014
  • Yurkovetskiy, (2017), Cancer Res., 77, pp. 48, 10.1158/1538-7445.AM2017-48
  • Pondé, (2019), Curr. Treat. Options Oncol., 20, 10.1007/s11864-019-0633-6
  • Bergstrom, (2016), Cancer Res., 76, pp. 4, 10.1158/1538-7445.SABCS15-P4-14-28
  • Paige, (2018), J. Clin. Oncol., pp. 2546
  • Yao, (2015), Breast Cancer Res. Treat., 153, pp. 123, 10.1007/s10549-015-3503-3
  • Binghe, (2018), J. Clin. Oncol., pp. 1028
  • Jiayu, (2018), J. Clin. Oncol., pp. 1030
  • Oganesyan, (2018), J. Biol. Chem., 293, pp. 8439, 10.1074/jbc.M117.818013
  • Pegram, (2018), Ann. Oncol., pp. 29
  • Naumovski, (2010), Curr. Opin. Mol. Therap., 12, pp. 248
  • Bendell, (2014), J. Clin. Oncol., 32, pp. 3619, 10.1200/JCO.2013.52.5683
  • Kaplon, (2019), mAbs, 11, pp. 219, 10.1080/19420862.2018.1556465
  • Sussman, (2014), Mol. Cancer Therap., 13, pp. 2991, 10.1158/1535-7163.MCT-13-0896
  • Zhang, (2016), Nat. Commun., pp. 7
  • Grattan, (2012), Nutrients, 4, pp. 648, 10.3390/nu4070648
  • Modi, (2018), Cancer Res., 78, pp. 3, 10.1158/1538-7445.SABCS17-PD3-14
  • Damelin, (2017), Sci. Transl. Med., 9, pp. 372, 10.1126/scitranslmed.aag2611
  • C., (2018), J. Clin. Oncol., pp. 5565
  • Wainberg, (2017), Target. Oncol., 12, pp. 775, 10.1007/s11523-017-0530-5
  • Nejadmoghaddam, (2019), Avicenna J. Med. Biotechnol., 11, pp. 3
  • Alberto, (2016), J. Clin. Oncol., pp. 2511
  • Garrido-Laguna, (2019), Int. J. Cancer, 145, pp. 1798, 10.1002/ijc.32154
  • Thomas, (2004), Bioorganic Med. Chem., 12, pp. 1585, 10.1016/j.bmc.2003.11.036
  • Weiss, (2013), Invest. N. Drugs, 31, pp. 986, 10.1007/s10637-012-9921-8
  • Rodallec, (2018), Int. J. Nanomed., 13, pp. 3451, 10.2147/IJN.S162454
  • Eloy, (2017), Eur. J. Pharm. Biopharm., 115, pp. 159, 10.1016/j.ejpb.2017.02.020
  • Vaidya, (2018), Pharm. Res., 35, 10.1007/s11095-018-2365-x
  • Pu, (2019), Eur. J. Med. Chem., pp. 183
  • Ju, (2018), Artif. Cells Nanomed. Biotechnol., 46, pp. 616, 10.1080/21691401.2018.1433187
  • Ghafari, (2020), J. Cell. Biochem., 121, pp. 3584, 10.1002/jcb.29651
  • Zhang, (2014), J. Pharm. Sci., 103, pp. 2177, 10.1002/jps.24019
  • Silva, (2019), Biomed. Pharmacother., pp. 118
  • Monteiro, (2019), Mol. Pharm., 16, pp. 3477, 10.1021/acs.molpharmaceut.9b00329
  • Franco, (2019), Biomed. Pharmacother., 109, pp. 1728, 10.1016/j.biopha.2018.11.011
  • Kang, (2018), Mol. Pharm., 15, pp. 1618, 10.1021/acs.molpharmaceut.7b01164
  • Varshosaz, (2018), Drug. Dev. Ind. Pharm., 44, pp. 1139, 10.1080/03639045.2018.1438462
  • Xiang, (2018), Sci. China Life Sci., 61, pp. 436, 10.1007/s11427-017-9274-9
  • He, (2016), Biomaterials, 101, pp. 296, 10.1016/j.biomaterials.2016.06.002
  • Wan, (2019), Biomaterials, 192, pp. 1, 10.1016/j.biomaterials.2018.10.032
  • Wang, (2017), Int. J. Nanomed., 12, pp. 1499, 10.2147/IJN.S124843
  • Patra, (2018), Int. J. Nanomed., 13, pp. 2869, 10.2147/IJN.S153094
  • Sau, (2019), Cancers, 11, 10.3390/cancers11020232
  • Jang, (2019), ChemistryOpen, 8, pp. 451, 10.1002/open.201900037
  • Sun, (2019), J. Microencapsul., 36, pp. 728, 10.1080/02652048.2019.1671908
  • Thadakapally, (2016), Indian J. Pharm. Sci., 78, pp. 65, 10.4103/0250-474X.180250
  • Chen, (2017), Pharmazie, 72, pp. 152
  • Lin, (2019), Pharmaceutics, 11, 10.3390/pharmaceutics11110569
  • Behrouz, (2016), Chem. Biol. Drug. Des., 88, pp. 230, 10.1111/cbdd.12750
  • Kushwah, (2018), Acta Biomater., 73, pp. 424, 10.1016/j.actbio.2018.03.057
  • Lu, (2019), J. Cancer, 10, pp. 2357, 10.7150/jca.30323
  • Mir, (2017), Colloids Surf. B: Biointerfaces, 159, pp. 217, 10.1016/j.colsurfb.2017.07.038
  • Vakilinezhad, (2019), Colloids Surf. B: Biointerfaces, pp. 184
  • Gao, (2019), Int. J. Nanomed., 14, pp. 9199, 10.2147/IJN.S230376
  • Xueyan, (2019), Dose-Response
  • Venugopal, (2018), PLoS ONE, 13, 10.1371/journal.pone.0206109
  • Gibbens-Bandala, (2019), Mater. Sci. Eng. C. Mater Biol. Appl., 105
  • Cabeza, (2017), Eur. J. Pharm. Sci., 102, pp. 24, 10.1016/j.ejps.2017.02.026
  • Eatemadi, (2016), Artif. Cells Nanomed. Biotechnol., 44, pp. 1008
  • Nosrati, (2018), J. Biomed. Mater. Res. A, 106, pp. 1646, 10.1002/jbm.a.36364
  • Salimi, (2018), Cancer Nanotechnol., 9, 10.1186/s12645-018-0042-8
  • Lugert, (2019), Int. J. Nanomed., 14, pp. 161, 10.2147/IJN.S187886
  • Wang, (2019), Int. J. Nanomed., 14, pp. 7665, 10.2147/IJN.S214377
  • Dong, (2019), Nanoscale Res. Lett., 14, 10.1186/s11671-019-3053-4